In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Medtronic InSync

This article was originally published in The Gray Sheet

Executive Summary

Medtronic InSync: Bi-ventricular cardiac stimulator for treament of congestive heart failure is "moving into the clinical trial phase in the U.S.," company Chairman and CEO William George tells investors at a Feb. 3 session of the Piper Jaffray medical device conference in New York City. The device, which paces both sides of the heart through a proprietary transvenous lead system, "is progressing quickly through its initial 60-patient human clinical in Europe as well as in Canada," George notes, adding that "the greatest long-term opportunity for Medtronic in the pacing business is the treatment of congestive heart failure with biventricular cardiac stimulation" technology...



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts